

[Generate Collection](#)[Print](#)

Search Results - Record(s) 1 through 17 of 17 returned.

1. [20090061031](#). 09 Jul 07. 05 Mar 09. Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus. Lee-Huang; Sylvia, et al. 424/774; 514/27 514/277 514/331 514/342 514/369 514/4 514/419 514/42 514/423 514/460 514/592 514/634 514/635 514/636 514/734 A61K31/05 20060101 A61K31/155 20060101 A61K31/175 20060101 A61K31/351 20060101 A61K31/366 20060101 A61K31/40 20060101 A61K31/404 20060101 A61K31/427 20060101 A61K31/435 20060101 A61K31/4439 20060101 A61K31/445 20060101 A61K31/70 20060101 A61K31/7036 20060101 A61K36/00 20060101 A61K38/28 20060101 A61P3/00 20060101 A61P31/12 20060101

2. [20080026084](#). 24 Jul 07. 31 Jan 08. Method and composition for management of weight and blood sugar. Subbiah; Ven. 424/725; 435/26 435/29 A61K36/42 20060101 A61P3/04 20060101 A61P3/10 20060101 C12Q1/02 20060101 C12Q1/32 20060101

3. [20070203225](#). 22 Mar 07. 30 Aug 07. METHOD OF INCREASING ENDOGENOUS ADIPONECTIN PRODUCTION AND LEPTIN PRODUCTION. Havel; Peter J., et al. 514/425; 514/557 514/568 514/621 A61K31/165 20060101 A61K31/19 20060101 A61K31/194 20060101 A61K31/40 20060101

4. [20060182825](#). 11 Feb 05. 17 Aug 06. Methods and compounds for the treatment of obesity and obesity-related disorders. Prasad; Chandan, et al. 424/760; 514/625 A61K31/16 20060101 A61K36/81 20060101

5. [20050261362](#). 22 Mar 05. 24 Nov 05. Method of increasing endogenous adiponectin and leptin production. Havel, Peter J., et al. 514/426; 514/557 514/562 A61K031/4015 A61K031/195 A61K031/19.

6. [20050008718](#). 06 Jul 04. 13 Jan 05. Identification of compositions, compositions, and methods of treatment of obesity and overweight conditions. Subbiah, Ven. 424/773; 514/26 A61K035/78 A61K031/7052.

7. [20040166061](#). 23 Mar 04. 26 Aug 04. Animal model. Enerback, Sven, et al. 424/9.2; 435/6 A61K049/00 C12Q001/68.

8. [20040097454](#). 06 May 03. 20 May 04. Method for modulation of cell phenotype. Reusch, Jane E., et al. 514/44; 435/6 A61K048/00 C12Q001/68.

9. [20040043929](#). 03 Jan 03. 04 Mar 04. Novel proteins and nucleic acids encoding same. Anderson, David W., et al. 514/12; 435/183 435/320.1 435/325 435/6 435/69.1 530/350 536/23.2 C12Q001/68 A61K038/17 C12P021/02 C12N005/06 C07K014/47 C07H021/04 C12N009/00.

10. [20030008838](#). 01 Apr 02. 09 Jan 03. Method of increasing endogenous leptin production. Havel, Peter J., et al. 514/44; 435/455 514/424 514/557 514/562 A61K048/00 A61K031/4015 A61K031/195 A61K031/19.

11. [7479540](#). 05 Apr 05; 20 Jan 09. Adipomodulin and related molecules and methods. Prasad; Chandan, et al. 530/350; 530/387.1 530/412 530/828 530/829 530/868. C07K14/00 20060101 .

12. [7226625](#). 06 Jul 04; 05 Jun 07. Identification of compositions, compositions, and methods of treatment of obesity and overweight conditions. Subbiah; Ven. 424/746; 514/8 549/299. A61K36/537 20060101 .

13. [6897019](#). 17 Oct 00; 24 May 05. Methods for treating and preventing insulin resistance and related disorders. Greenberg; Andrew S.. 435/6; 435/7.1 530/300 530/350 530/387.1 536/23.1 536/24.5. C12Q001/68 G01N033/53 C07K005/00 C07K014/00 C07K016/00 .

14. [6709860](#). 06 Jun 00; 23 Mar 04. Animal model. Enerback; Sven, et al. 435/320.1; 536/23.1 536/23.5. C07H021/04 C12N015/00 .

Record List Display

15. [6015558](#). 10 Mar 98; 18 Jan 00. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-.alpha. function. Hotamisligil; Gokhan S., et al. 424/142.1; 424/130.1 424/145.1 424/158.1. A61K039/395 .

16. [5730975](#). 08 Jun 94; 24 Mar 98. Treatment of insulin resistance in obesity linked type II diabetes using antagonist to TNF-alpha function. Hotamisligil; Gokhan S., et al. 424/130.1; 424/141.1 424/143.1 424/145.1 424/158.1 424/184.1 424/192.1 424/85.1 514/263.31 514/929 530/351 530/388.23. C07K016/24 C07K014/52 A61K038/11 C07H019/00 .

17. WO 0206450 A1. New human pre-adipose cell line capable of differentiating to adipose cells, useful in developing drug, food ingredients, and supplements against obesity, diabetes and cardiovascular diseases. DARIMONT C, et al.

 [Generate Collection](#)  [Print](#)

Terms	Documents
L15 and L16	17

[Prev Page](#) [Next Page](#) [Go to Doc#](#)